These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 456389)

  • 41. 5-Hydroxyindoleacetic acid and homovanillic acid in human cerebrospinal fluid below partial and complete spinal subarachnoid block.
    Massarotti M; Roccella P; Toffano G
    Eur Neurol; 1978; 17(3):174-80. PubMed ID: 658062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CSF-changes of HVA and 5-HIAA during intermittent and continuous Parkinson therapy with particular regard to prodipin application.
    Oppel F; Schulze G
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):76-80. PubMed ID: 347467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimation of monoamine and cyclic-AMP turnover and amino acid concentrations of spinal fluid in autistic children.
    Winsberg BG; Sverd J; Castells S; Hurwic M; Perel JM
    Neuropediatrics; 1980 Aug; 11(3):250-5. PubMed ID: 6158716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diphenylhydantoin as an anticonvulsant: protein binding and fluctuation of the serum and cerebrospinal fluid levels in forty mentally subnormal epileptics.
    Viukari NM; Tammisto P
    J Ment Defic Res; 1969 Dec; 13(4):235-44. PubMed ID: 4983146
    [No Abstract]   [Full Text] [Related]  

  • 45. [Effect of diphenylhydantoin on a developed epileptogenic focus in cats with split cerebral hemispheres].
    Bilińska-Nigot B; Majkowski J
    Neurol Neurochir Pol; 1976; 10(2):231-6. PubMed ID: 1264339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cerebrospinal fluid levels of HVA and 5-HIAA in epileptic patients: effect of total sleep deprivation].
    Livrea P; Di Reda L; Papagno G
    Acta Neurol (Napoli); 1976; 31(5):632-6. PubMed ID: 827926
    [No Abstract]   [Full Text] [Related]  

  • 47. Chronic diphenyl hydantoin encephalopathy in mentally retarded children and adolescent with severe epilepsy.
    Meistrup-Larsen KI; Hermann S; Permin H
    Acta Neurol Scand; 1979 Jul; 60(1):50-5. PubMed ID: 495042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Folate treatment of diphenylhydantoin-induced gingival hyperplasia.
    Bäckman N; Holm AK; Hänström L; Blomquist HK; Heijbel J; Säfström G
    Scand J Dent Res; 1989 Jun; 97(3):222-32. PubMed ID: 2740833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chromosomal damage in epileptics on monotherapy with carbamazepine and diphenylhydantoin.
    Herha J; Obe G
    Hum Genet; 1976 Dec; 34(3):255-63. PubMed ID: 1002148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Side effects of antiepileptic drugs: a peripheral neuropathy due to diphenylhydantoin (DPH) intoxication.
    Uchigata M; Nozawa T; Shiozawa R; Tanabe H
    Folia Psychiatr Neurol Jpn; 1980; 34(3):314-5. PubMed ID: 6260604
    [No Abstract]   [Full Text] [Related]  

  • 51. Bioavailability of four brands of phenytoin tablets.
    Pentikäinen PJ; Neuvonen PJ; Elfving SM
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):213-8. PubMed ID: 1243985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A quantitative study of the acute effects of diphenylhydantoin on the electroencephalogram of epileptic patients. Theoretical considerations for its use in the treatment of status epilepticus.
    Riehl JL; McIntyre HB
    Neurology; 1968 Nov; 18(11):1107-12. PubMed ID: 5751917
    [No Abstract]   [Full Text] [Related]  

  • 53. Phenytoin encephalopathy as probable idiosyncratic reaction: case report.
    Ambrosetto G; Tassinari CA; Baruzzi A; Lugaresi E
    Epilepsia; 1977 Sep; 18(3):405-8. PubMed ID: 891494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protein binding and CSF penetration of phenytoin following acute oral dosing in man.
    Brodie MJ; Muir SE; Agnew E; MacPhee GJ; Volo G; Teasdale E; MacPherson P
    Br J Clin Pharmacol; 1985 Feb; 19(2):161-8. PubMed ID: 3986076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A case of amyloidosis associated with diphenylhydantoin therapy.
    Nomura S; Osawa G; Sato T; Ishimatsu T; Shindo T; Hirano H
    Jpn J Med; 1989; 28(5):636-9. PubMed ID: 2511368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diphenylhydantoin-induced severe yet reversible anemia during pregnancy.
    Sugaya A; Nakamagoe K; Okoshi Y; Obata-Yasuoka M; Tamaoka A
    Intern Med; 2010; 49(22):2515-8. PubMed ID: 21088360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma levels of diphenylhydantoin and the control of adult epileptic seizures: a Chilean experience.
    Galdames DG; Saavedra IN; Ortiz MA; Aguilera LI; Valenzuela AL; Concha GL; Droguett PA; Morales ER
    Epilepsia; 1980 Oct; 21(5):467-74. PubMed ID: 6774870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of diphenylhydantoin in epilepsy treatment.
    Gordon N
    Dev Med Child Neurol; 1969 Feb; 11(1):111-2. PubMed ID: 5786055
    [No Abstract]   [Full Text] [Related]  

  • 59. Diphenylhydantoin serum levels, toxicity, and neuropsychological performance in patients with epilepsy.
    Dodrill CB
    Epilepsia; 1975 Nov; 16(4):593-600. PubMed ID: 1204595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diphenylhydantoin and pulmonary function.
    Smith RJ; Man GC; Man SF; McLean DR
    Can J Neurol Sci; 1979 Feb; 6(1):21-5. PubMed ID: 264153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.